Nasdaq
$8.70▼ 7.15%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $18.1MShares out 2.1M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
11- 10.7After-hours26.10.08 05:15S-8Offering#●●●
Polyrizon Ltd.
Polyrizon Ltd. has filed a Form S-8 registration statement to register an additional 250,000 ordinary shares for issuance under its Amended and Restated Equity Incentive Plan. This registration covers shares intended for employee stock-based compensation, with a maximum aggregate offering price of $2,502,500 based on an estimated price of $10.01 per share.…more
$8.70-7.15%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 10.5After-hours26.10.06 05:006-KKey event
Polyrizon Ltd.
Polyrizon has filed a new divisional patent application with the USPTO to strengthen the intellectual property surrounding its intranasal drug-delivery platform. The application, numbered 19/823,285, focuses on mucoadhesive polymer technology and aims to expand the company's foundation for developing nasal-based therapeutic delivery systems.…more
$8.70-7.15%vs prev closeView filingShare - 10.2Pre-market26.10.02 13:15filedEFFECTOther
Polyrizon Ltd.
The registration statement filed by Polyrizon Ltd. has been declared effective by the SEC as of October 1, 2026. This effectiveness allows the company to proceed with the offering and issuance of securities as detailed in the filing.…more
$8.70-7.15%vs prev closeView filingShare
10 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswire- 10.5Pre-market26.10.05 20:32#●●●#●●●
Polyrizon Files for U.S. Patent to Expand Nasal Drug Delivery Platform
Polyrizon has filed a new U.S. patent application to strengthen its intellectual property portfolio regarding its proprietary mucoadhesive nasal drug delivery technology. While this move expands the company's IP moat, the actual issuance of the patent remains subject to regulatory approval.…more
$8.70-7.15%vs prev closeDetected5m · 30m · 60m · Next dayPLUS
- 9.22Pre-market26.09.22 21:33
●●●●●●●● ●●●●● ●●●●●●
Polyrizon has officially entered the clinical stage by enrolling the first patient in its U.S. study for the drug-free allergy blocker NASARIX. The multicenter trial aims to evaluate the efficacy and safety of the treatment in 120 patients with seasonal allergic rhinitis.…more
$8.70-7.15%vs prev close - 9.4Regular26.09.05 00:58
●●●●●●●● ●●●●● ●●●●●●
Polyrizon Ltd. has completed a $4 million registered direct offering and concurrent private placement. The proceeds will be used for general corporate purposes and working capital, resulting in share dilution.…more
$8.70-7.15%vs prev close
2 more news items
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report